Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Biotechnology company Allergy Therapeutics reported a slight decline in first-half as an uptick in administrative expenses offset sales growth.
For the six months ended 31 December 2020, pre-tax profit slipped to £15.6 million from £15.9 million year-on-year, while revenue increased by 7% to £54.0 million.
The company's pre-R&D operating profit hit a record of £20.5 million as a result of continued sales growth and operational efficiency.
Administrative expenses climbed to £14.3 million from £9.5 million, owing to investment in compliance and infrastructure.
The company's pre-Investigational new drug meeting with FDA for its VLP peanut programme is scheduled for H1 2021.
At 10:04am: (LON:AGY) Allergy Therapeutics PLC share price was 0p at 13.88p